Samarth Kulkarni

CIK 1682019 · Chief Executive Officer · last filed 2026-06-29

Samarth Kulkarni is a Chief Executive Officer who has filed 123 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing, for BDTX, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$65.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$16.25M

Companies

6

Total Filings

123

Lifetime Open-Market Net

-$65.03M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BDTX Director $1.69 $0 7 2026-06-29
Centessa Pharmaceuticals plc (CNTA) Delisted Director $40.50 $0 5 2026-06-24
ORKA Director $87.84 $0 2 2026-06-03
CRSP Chief Executive Officer 341,123 $47.64 $16.25M -$64.02M 87 2026-03-24
Repare Therapeutics Inc. (RPTX) Delisted Director $2.65 $0 4 2024-06-20
CRISPR Therapeutics AG (PZRX) Delisted Chief Executive Officer 148,560 -$1.01M 7 2017-12-26

Recent Filings

123 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-29 BDTX Grant (A) $0 EDGAR
2026-06-24 Centessa Pharmaceuticals plc (CNTA) Delisted Disp (D) $0 EDGAR
2026-06-03 ORKA Grant (A) $0 EDGAR
2026-03-24 CRSP Mixed +9,667 -$468.7K EDGAR
2026-03-17 CRSP Mixed +10,276 -$499.4K EDGAR
2026-03-12 CRSP Mixed +9,452 -$517.3K EDGAR
2026-02-20 CRSP Mixed +6,283 -$366.3K EDGAR
2026-01-22 CRSP Notice (144) −60,000 -$3.65M EDGAR
2026-01-22 CRSP Sell (S) −90,000 -$5.17M EDGAR
2026-01-20 CRSP Notice (144) −30,000 -$1.58M EDGAR
Showing 110 of 123
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.